WO2007025286A3 - Therapy procedure for drug delivery for trigeminal pain - Google Patents

Therapy procedure for drug delivery for trigeminal pain Download PDF

Info

Publication number
WO2007025286A3
WO2007025286A3 PCT/US2006/033672 US2006033672W WO2007025286A3 WO 2007025286 A3 WO2007025286 A3 WO 2007025286A3 US 2006033672 W US2006033672 W US 2006033672W WO 2007025286 A3 WO2007025286 A3 WO 2007025286A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug delivery
therapy procedure
trigeminal pain
pain
trigeminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/033672
Other languages
French (fr)
Other versions
WO2007025286A2 (en
Inventor
David C Yeomans
William H Ii Frey
Daniel I Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to JP2008528248A priority Critical patent/JP2009506076A/en
Priority to EP06813886.6A priority patent/EP2056800B1/en
Priority to CA2620202A priority patent/CA2620202C/en
Priority to US11/990,878 priority patent/US20090317377A1/en
Publication of WO2007025286A2 publication Critical patent/WO2007025286A2/en
Publication of WO2007025286A3 publication Critical patent/WO2007025286A3/en
Anticipated expiration legal-status Critical
Priority to US12/409,413 priority patent/US20100080797A1/en
Priority to US13/165,646 priority patent/US8258096B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region.
PCT/US2006/033672 2005-08-26 2006-08-28 Therapy procedure for drug delivery for trigeminal pain Ceased WO2007025286A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2008528248A JP2009506076A (en) 2005-08-26 2006-08-28 Therapeutic procedures for drug delivery for trigeminal neuralgia
EP06813886.6A EP2056800B1 (en) 2005-08-26 2006-08-28 Therapy procedure for drug delivery for trigeminal pain
CA2620202A CA2620202C (en) 2005-08-26 2006-08-28 Therapy procedure for drug delivery for trigeminal pain
US11/990,878 US20090317377A1 (en) 2005-08-26 2006-08-28 Therapy procedure for drug delivery for trigeminal pain
US12/409,413 US20100080797A1 (en) 2005-08-26 2009-03-23 Therapy procedure for drug delivery for trigeminal pain
US13/165,646 US8258096B2 (en) 2005-08-26 2011-06-21 Therapy procedure for drug delivery for trigeminal pain

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71195005P 2005-08-26 2005-08-26
US60/711,950 2005-08-26
US79400406P 2006-04-21 2006-04-21
US60/794,004 2006-04-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/990,878 A-371-Of-International US20090317377A1 (en) 2005-08-26 2006-08-28 Therapy procedure for drug delivery for trigeminal pain
US12/409,413 Continuation US20100080797A1 (en) 2005-08-26 2009-03-23 Therapy procedure for drug delivery for trigeminal pain

Publications (2)

Publication Number Publication Date
WO2007025286A2 WO2007025286A2 (en) 2007-03-01
WO2007025286A3 true WO2007025286A3 (en) 2007-05-10

Family

ID=37654909

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/033500 Ceased WO2007025249A2 (en) 2005-08-26 2006-08-28 Methods for treatment of headaches by administration of oxytocin
PCT/US2006/033672 Ceased WO2007025286A2 (en) 2005-08-26 2006-08-28 Therapy procedure for drug delivery for trigeminal pain

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2006/033500 Ceased WO2007025249A2 (en) 2005-08-26 2006-08-28 Methods for treatment of headaches by administration of oxytocin

Country Status (9)

Country Link
US (9) US20070093420A1 (en)
EP (3) EP1928484B1 (en)
JP (4) JP2009506076A (en)
AT (1) ATE458491T1 (en)
AU (1) AU2006282799B2 (en)
CA (2) CA2620202C (en)
DE (1) DE602006012513D1 (en)
IL (1) IL189777A0 (en)
WO (2) WO2007025249A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198240B2 (en) 2005-08-26 2012-06-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
US9629894B2 (en) 2015-01-07 2017-04-25 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
KR101441843B1 (en) 2005-10-18 2014-09-17 내셔날 쥬이쉬 헬스 Conditionally immortalized long-term stem cells and methods of making and using such cells
MY153249A (en) 2005-11-14 2015-01-29 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US20080261893A1 (en) * 2006-02-24 2008-10-23 Denise Barbut Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
WO2007120485A2 (en) * 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
EP2131651B1 (en) * 2007-03-12 2013-05-22 Sarentis Therapeutics, Inc. Topical corneal analgesia using neurotensin receptor agonists
EP2134852A4 (en) * 2007-03-13 2010-04-28 Nat Jewish Health METHODS OF GENERATING ANTIBODIES
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
EP2152240A4 (en) * 2007-06-08 2012-05-09 Healthpartners Res Foundation PHARMACEUTICAL COMPOSITIONS AND METHODS FOR AMPLIFYING THE TARGETING OF THERAPEUTIC COMPOUNDS ON THE CENTRAL NERVOUS SYSTEM
WO2009012376A1 (en) * 2007-07-17 2009-01-22 The Ohio State University Research Foundation Compositions and methods for skin care
EP2197469A2 (en) * 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection
WO2009043440A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent
RU2010114025A (en) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) APPLICATION OF THE Gly-Arg-Gly-Asp-Asn-Pro PEPTIDE AS A THERAPEUTIC
WO2009046848A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent
WO2009033489A2 (en) * 2007-09-11 2009-03-19 Glostrup Hospital Selective pacl inhibitors for use in the treatment of migraine and headaches
CA2716424C (en) 2008-03-04 2015-04-28 Pfizer Limited Methods of treating chronic pain
WO2009145956A2 (en) * 2008-03-06 2009-12-03 The Trustees Of Columbia University In The City Of New York Uses of calpain inhibitors to inhibit inflammation
US20090246273A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Ketorolac Sublingual Spray for the Treatment of Pain
EP2285832B1 (en) 2008-05-16 2020-08-26 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
FR2932483A1 (en) * 2008-06-13 2009-12-18 Cytomics Systems COMPOUNDS USEFUL FOR THE TREATMENT OF CANCERS.
ES2525411T3 (en) * 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Differentiated anucleated cells and method to prepare them
EP2318435B1 (en) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
WO2010029555A1 (en) * 2008-09-12 2010-03-18 Slender Medical, Ltd. Virtual ultrasonic scissors
US20110318345A1 (en) * 2008-09-15 2011-12-29 Optinose As Nasal delivery
US8802681B2 (en) * 2008-10-17 2014-08-12 Signature Therapeutics, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
US8575309B2 (en) 2008-12-08 2013-11-05 Biousian Biosystems, Inc. Delta-opioid receptor selective analgesics
EP2393488B1 (en) * 2009-02-06 2019-06-19 University Of Southern California Therapeutic compositions comprising monoterpenes
JP2012526840A (en) * 2009-05-13 2012-11-01 プロテイン デリヴァリー ソリューションズ エルエルシー Formulation system for transmembrane delivery
US9107876B2 (en) 2009-07-02 2015-08-18 Yamaguchi University Surface anesthetic agent
SG10201406930UA (en) * 2009-07-27 2014-11-27 Nocicepta Llc Methods For Treatment Of Pain
FR2948809B1 (en) * 2009-07-31 2012-08-17 St Microelectronics Rousset LOW POWER SELF-MINUTE READING AMPLIFIER
KR101519192B1 (en) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
BR112012005124B1 (en) 2009-09-08 2021-11-09 Signature Therapeutics, Inc. KETONE-MODIFIED OPIOID PRO-DRUG, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, DOSAGE UNIT, METHODS AND USES
WO2011075688A1 (en) * 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
US8622993B2 (en) * 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
US20110184322A1 (en) * 2010-01-22 2011-07-28 Slender Medical Ltd. Method and device for treatment of keloids and hypertrophic scars using focused ultrasound
EP2542082B8 (en) 2010-03-03 2020-06-17 Neonc Technologies Inc. PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-perillyl alcohol
US9238020B2 (en) 2010-04-21 2016-01-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
US20130089504A1 (en) * 2010-04-21 2013-04-11 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Hydromorphone Prodrug
US9242122B2 (en) 2010-05-14 2016-01-26 Liat Tsoref Reflectance-facilitated ultrasound treatment and monitoring
US8956346B2 (en) 2010-05-14 2015-02-17 Rainbow Medical, Ltd. Reflectance-facilitated ultrasound treatment and monitoring
US8617150B2 (en) 2010-05-14 2013-12-31 Liat Tsoref Reflectance-facilitated ultrasound treatment
EP2571511B1 (en) 2010-05-18 2014-10-08 Université de Genève New uses of oxytocin-like molecules and related methods
AR082189A1 (en) * 2010-07-06 2012-11-21 Gruenenthal Gmbh GASTRORTENTIVE DOSAGE FORMS, PROCEDURE
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
DK3685835T3 (en) 2010-08-27 2025-07-21 Univ Southern California PHARMACEUTICAL COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVES
GB201015371D0 (en) * 2010-09-14 2010-10-27 Optinose As Nasal delivery
US8647661B1 (en) * 2010-11-05 2014-02-11 Florida A&M University Surface modified multilayered nanostructures for dermal delivery
ES3056006T3 (en) 2010-12-17 2026-02-17 Univ Southern California Methods and devices for using isoperillyl alcohol
ES2584634T3 (en) 2011-01-11 2016-09-28 Signature Therapeutics, Inc. Compositions comprising an enzymatically cleavable oxycodone prodrug
WO2012096886A1 (en) 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
US20120183580A1 (en) * 2011-01-13 2012-07-19 Theralpha Analgesic Composition for Transbuccal Administration
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10687975B2 (en) * 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
AU2012225337B2 (en) 2011-03-09 2016-04-28 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
WO2012123819A1 (en) 2011-03-15 2012-09-20 Optinose As Et Al Nasal delivery
RS58064B1 (en) 2011-04-05 2019-02-28 Gruenenthal Gmbh Tapentadol for preventing chronification of pain
US20120309840A1 (en) * 2011-04-05 2012-12-06 Gruenenthal Gmbh Treatment of Pain Associated with Trigeminal Neuralgia
LT3272343T (en) 2011-04-29 2020-05-11 Grünenthal GmbH Tapentadol for preventing and treating depression and anxiety
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
WO2012174481A1 (en) 2011-06-15 2012-12-20 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
US9962391B2 (en) 2011-12-27 2018-05-08 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213501B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213500B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US10813897B2 (en) 2011-12-27 2020-10-27 Cmpd Licensing, Llc Composition and method for compounded therapy
US20130178419A1 (en) * 2012-01-05 2013-07-11 Beech Tree Labs, Inc. Method of treating pain by administration of nerve growth factor
US9707414B2 (en) 2012-02-14 2017-07-18 Rainbow Medical Ltd. Reflectance-facilitated ultrasound treatment and monitoring
WO2013122778A1 (en) 2012-02-15 2013-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing diseases and disorders of the central nervous system
JP6285930B2 (en) 2012-07-20 2018-02-28 タイガ バイオテクノロジーズ，インク． Rebuilding hematopoietic compartments and promoting self-rebuilding
ES2442242B1 (en) * 2012-08-09 2014-11-25 Biotechnology Institute, I Mas D, S.L. Composition with growth factors intended for intranasal treatment of a neurodegenerative disease or other pathology of the central nervous system, and its manufacturing method.
US9770593B2 (en) 2012-11-05 2017-09-26 Pythagoras Medical Ltd. Patient selection using a transluminally-applied electric current
WO2014068577A2 (en) 2012-11-05 2014-05-08 Rainbow Medical Ltd. Controlled tissue ablation
CN104813167B (en) * 2012-11-28 2019-04-09 尼克塔治疗公司 Method for assessing and predicting the efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor
US9050330B2 (en) * 2012-12-06 2015-06-09 Jose C. Ramon-de-Jesus Method, composition and kit for treating frequent headaches
US10639439B2 (en) 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof
WO2014130581A1 (en) * 2013-02-20 2014-08-28 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
CA2906737C (en) 2013-03-15 2023-08-15 Amgen Inc. Human pac1 antibodies
CN105377039A (en) 2013-05-15 2016-03-02 明尼苏达大学董事会 Adeno-associated virus-mediated gene transfer to the central nervous system
US20150086616A1 (en) * 2013-09-20 2015-03-26 Steven Lehrer Method for the prevention and treatment of alzheimer's disease
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
PE20161439A1 (en) 2014-03-21 2017-01-26 Teva Pharmaceuticals Int Gmbh ANTIBODIES ANTAGONISTS DIRECTED AGAINST THE PEPTIDE RELATED TO THE CALCITONIN GENE AND METHODS USING THE SAME
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2015170281A1 (en) 2014-05-07 2015-11-12 Rainbow Medical Ltd Controlled tissue ablation techniques
WO2015195708A1 (en) * 2014-06-16 2015-12-23 Loewi LLC Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof
WO2016044224A1 (en) 2014-09-15 2016-03-24 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
RU2701199C2 (en) * 2014-10-01 2019-09-25 Окситон Байосайенс Б.В. Orally disintegrating solid pharmaceutical dosage unit containing partus control substance
PL3200764T3 (en) * 2014-10-01 2020-12-28 Oxytone Bioscience B.V. Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance
SG10202011669PA (en) 2014-10-20 2020-12-30 Oyster Point Pharma Inc Methods of treating ocular conditions
AU2015335907A1 (en) 2014-10-21 2017-04-13 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
MY188242A (en) 2014-11-19 2021-11-24 Optinose As Intranasal administration
EP3226972A4 (en) 2014-12-01 2018-08-08 Achelios Therapeutics, Inc. Methods and compositions for treating migraine and conditions associated with pain
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
JP6674957B2 (en) 2015-02-12 2020-04-01 ネオンク テクノロジーズ インク． Pharmaceutical composition containing perillyl alcohol derivative
JP6734258B2 (en) * 2015-03-04 2020-08-05 栄研化学株式会社 Highly sensitive assay for oxytocin
CA2982861A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
US10383685B2 (en) 2015-05-07 2019-08-20 Pythagoras Medical Ltd. Techniques for use with nerve tissue
US11207461B2 (en) 2015-07-30 2021-12-28 Anoop U. R Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
US11213480B1 (en) 2015-08-06 2022-01-04 Hikma Pharmaceuticals International Limited Phenylephrine hydrochloride ready-to-use solution
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
JP2018534269A (en) 2015-10-01 2018-11-22 エリージウム セラピューティクス， インコーポレイテッド Polysubunit opioid prodrugs resistant to overdose and abuse
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
HUE070412T2 (en) * 2016-04-12 2025-06-28 Tonix Pharma Ltd Magnesium-containing oxytocin formulations and methods of use
EP3426288A4 (en) 2016-04-15 2019-10-30 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF
IL305449B2 (en) 2016-04-15 2026-01-01 Univ Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
US11678932B2 (en) 2016-05-18 2023-06-20 Symap Medical (Suzhou) Limited Electrode catheter with incremental advancement
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
WO2018094376A1 (en) * 2016-11-21 2018-05-24 uBiome, Inc. Method and system for characterizing a headache-related condition
EP3547836B1 (en) 2016-11-30 2024-08-21 University of Southern California A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
KR20190092472A (en) 2016-12-02 2019-08-07 타이가 바이오테크놀로지스, 인코포레이티드 Nanoparticle Formulation
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
EP3595663A4 (en) 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. MULTI-UNIT OPIOID MEDICINES RESISTANT TO OVERDOSE AND ABUSE
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
TWI835747B (en) 2017-09-22 2024-03-21 賓州大學委員會 Gene therapy for treating mucopolysaccharidosis type ii
UY38050A (en) * 2018-01-12 2019-07-31 Amgen Inc PAC1 ANTIBODIES AND THEIR USES CROSSED REFERENCE TO RELATED APPLICATIONS
CN111936125B (en) 2018-02-08 2025-03-04 南加州大学 Methods of penetrating the blood-brain barrier
US20210346385A1 (en) * 2018-09-21 2021-11-11 MSB Holdings, Inc Taste-masked dosage forms
US11135379B2 (en) 2019-02-15 2021-10-05 Bn Intellectual Properties, Inc. Method of delivering pharmaceutical products
CA3132082A1 (en) 2019-03-14 2020-09-17 Om Pharma Sa Method of treating and/or preventing asthma, asthma exacerbations, allergic asthma and/or associated conditions with microbiota related to respiratory disorders
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
EP3969041A4 (en) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR TREATING T LYMPHOCYTE DEPLETION
WO2021016190A1 (en) * 2019-07-19 2021-01-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for modulating drug-use disorders
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
CA3152988A1 (en) * 2019-08-29 2021-03-04 New York University Oxytocin compositions for treatment of tinnitus
WO2021072055A1 (en) * 2019-10-11 2021-04-15 Board Of Regents, The University Of Texas System Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression
WO2021151100A1 (en) 2020-01-24 2021-07-29 Aim Immunotech Inc. Methods, compositions, and vaccines for treating a virus infection
WO2023048748A1 (en) * 2020-08-10 2023-03-30 Ziropa, Inc. Compositions and methods for topical delivery
US12599578B2 (en) 2021-03-09 2026-04-14 Ensysce Biosciences Inc. Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof
MX2024003466A (en) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Enzyme-cleavable methadone prodrugs and methods of use thereof.
WO2023146579A1 (en) * 2022-01-27 2023-08-03 Belnap Pharmaceuticals, Llc Methods of treatment using oxytocin
AU2023375349A1 (en) * 2022-11-07 2025-05-22 AEON Biopharma, Inc. Compositions for use in treating headache disorders
WO2025064708A1 (en) * 2023-09-22 2025-03-27 The George Washington University Compositions comprising oxytocin and methods of treating opioid overdose
WO2025199179A2 (en) 2024-03-18 2025-09-25 Tonix Pharmaceuticals Holding Corp. Oxytocin peptide analogs

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885287A (en) * 1988-08-09 1989-12-05 University Of Kentucky Research Foundation Novel method of administering aspirin and dosage forms containing same
WO1991007947A1 (en) * 1989-12-05 1991-06-13 Ramsey Foundation Neurologic agents for nasal administration to the brain
WO1993017037A1 (en) * 1992-02-21 1993-09-02 Sandoz Ltd. Treatment of acute migraine or cluster headache attacks
WO1998042275A1 (en) * 1997-03-24 1998-10-01 Adolor Corporation Method of treatment of migraine
US6090368A (en) * 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
US6139861A (en) * 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
WO2001041732A1 (en) * 1999-12-06 2001-06-14 Gore Stanley L Compositions and methods for intranasal delivery of active agents to the brain
US20010055607A1 (en) * 1997-07-21 2001-12-27 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US6413499B1 (en) * 2000-01-06 2002-07-02 Bryan M. Clay Methods and kits for maxillary dental anesthesia by means of a nasal deliverable anesthetic
US20030072793A1 (en) * 1998-12-09 2003-04-17 Chiron Corporation Method for administering agents to the central nervous system
US20030119892A1 (en) * 2001-01-05 2003-06-26 Larry Caldwell Methods and compositions for treating headache pain with topical NSAID compositions
US20030185872A1 (en) * 2002-03-27 2003-10-02 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US20040120896A1 (en) * 1997-10-01 2004-06-24 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20040204366A1 (en) * 2001-04-27 2004-10-14 Gavril Pasternak Topical anesthetic/opioid formulation and uses thereof
US20050142072A1 (en) * 2002-03-19 2005-06-30 Birch Phillip J. Analgesics for nasal administration

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US464378A (en) * 1891-12-01 Toilet-paper holder
US6413A (en) * 1849-05-01 Improved method of making wire-strengthened spoons
US2938891A (en) * 1956-03-30 1960-05-31 Roussel Uclaf Method of making oxytocin and intermediates thereof
US3076797A (en) * 1957-07-22 1963-02-05 Roussel Uclaf Process of producing oxytocin and intermediates obtained thereby
US4213968A (en) * 1978-06-05 1980-07-22 Coy David Howard Enkephalin derivatives
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4486441A (en) * 1982-12-03 1984-12-04 Merrell Toraude Et Compagnie Pseudotropyl halogeno-benzoates and their use in migraine treatment
DE3686025T2 (en) 1985-05-22 1993-01-07 Liposome Technology Inc METHOD AND SYSTEM FOR INHALING LIPOSOMES.
NL194729C (en) * 1986-10-13 2003-01-07 Novartis Ag Process for the preparation of peptide alcohols via solid phase.
ATE99543T1 (en) * 1987-10-15 1994-01-15 Syntex Inc POWDERED PREPARATIONS FOR INTRANASAL ADMINISTRATION OF POLYPEPTIDES.
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6407061B1 (en) * 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE4312913A1 (en) * 1992-10-23 1994-10-13 Knauf Siegfried Oxytocin, vasopressin and alpha beta gamma -endorphin medicament composition
SE9300937L (en) * 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Composition for oral administration of peptides
US6054462A (en) * 1994-04-13 2000-04-25 Janssen Pharmaceutica, N.V. Intranasal antimigraine compositions
WO1996020001A1 (en) * 1994-12-28 1996-07-04 Teikoku Hormone Mfg. Co., Ltd. Transmucosal preparation
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
ATE247456T1 (en) * 1996-02-27 2003-09-15 Teijin Ltd POWDER COMPOSITION FOR NASAL USE
SE9701162D0 (en) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
SE9701161D0 (en) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
ES2252993T3 (en) * 1998-12-09 2006-05-16 Chiron Corporation ADMINISTRATION OF NEUROTROPHIC AGENTS TO THE CENTRAL NERVOUS SYSTEM.
AU2173400A (en) 1998-12-09 2000-06-26 Chiron Corporation Method for administering agents to the central nervous system
HRP20010926A2 (en) * 1999-06-16 2003-04-30 Nastech Pharmaceutical Co Pharmaceutical formulations and methods comprising intranasal morphine
JP2001002589A (en) * 1999-06-18 2001-01-09 Teijin Ltd Composition for nasal administration capable of moderately increasing blood concentration of drug
JP2001089359A (en) * 1999-09-24 2001-04-03 Toko Yakuhin Kogyo Kk Gel or sol formulation for nasal drops of analgesic component
EP1237567B1 (en) * 1999-12-09 2005-08-03 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
KR20030060771A (en) * 2000-04-28 2003-07-16 메모리얼 슬로안-케터링 캔서 센터 Topical anesthetic/opioid formulations and uses thereof
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
AU2001262992A1 (en) * 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
EP1370282A2 (en) * 2000-10-13 2003-12-17 Chiron Corporation Method for treating ischemic events affecting the central nervous system
AU2002305066B8 (en) 2001-03-23 2008-04-17 Albert Einstein College Of Medicine Of Yeshiva University Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting GM1-ganglioside
US20020169102A1 (en) 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
WO2002086105A1 (en) 2001-04-20 2002-10-31 Chiron Corporation Delivery of polynucleotide agents to the central nervous sysstem
US20030104085A1 (en) * 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
EP1487474A4 (en) * 2002-02-25 2006-11-29 Chiron Corp Intranasal administration of mc4-r agonists
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
AU2003234185C1 (en) * 2002-04-22 2009-11-19 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C
AU2003229735A1 (en) 2002-05-02 2003-11-17 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
AU2003273247A1 (en) 2002-08-30 2004-03-19 Board Of Regents, The University Of Texas System Non-invasive methods to identify agents for treating pain
US7065445B2 (en) * 2002-11-27 2006-06-20 Mobilearia Vehicle passive alert system and method
WO2004062563A2 (en) 2003-01-16 2004-07-29 Université de Lausanne Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders
DE60323938D1 (en) * 2003-03-27 2008-11-20 Pantarhei Bioscience Bv Use of estrogens for the treatment of male infertility
CA2520655A1 (en) 2003-04-08 2004-11-04 Biotempt, B.V. Compositions for mucosal and oral administration comprising hcg fragments
WO2004093145A2 (en) * 2003-04-11 2004-10-28 Paratek Microwave, Inc. Voltage tunable photodefinable dielectric and method of manufacture therefore
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
US20080103209A1 (en) 2004-04-23 2008-05-01 The Regents Of The University Of California Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7618615B2 (en) * 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
NZ581205A (en) * 2005-02-23 2011-06-30 Alza Corp Intranasal administration of active agents to the central nervous system
EP2455072A1 (en) * 2005-03-11 2012-05-23 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
US20060252685A1 (en) * 2005-05-04 2006-11-09 Gould Jeffrey D Treatment for sleep apnea
CA2620202C (en) 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
CN101404174B (en) * 2007-10-04 2010-06-09 威刚科技股份有限公司 Electronic information storage device

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885287A (en) * 1988-08-09 1989-12-05 University Of Kentucky Research Foundation Novel method of administering aspirin and dosage forms containing same
WO1991007947A1 (en) * 1989-12-05 1991-06-13 Ramsey Foundation Neurologic agents for nasal administration to the brain
WO1993017037A1 (en) * 1992-02-21 1993-09-02 Sandoz Ltd. Treatment of acute migraine or cluster headache attacks
WO1998042275A1 (en) * 1997-03-24 1998-10-01 Adolor Corporation Method of treatment of migraine
US20010055607A1 (en) * 1997-07-21 2001-12-27 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US20040120896A1 (en) * 1997-10-01 2004-06-24 Novadel Pharma, Inc. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6090368A (en) * 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
US20030072793A1 (en) * 1998-12-09 2003-04-17 Chiron Corporation Method for administering agents to the central nervous system
US6139861A (en) * 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
WO2001041732A1 (en) * 1999-12-06 2001-06-14 Gore Stanley L Compositions and methods for intranasal delivery of active agents to the brain
US6413499B1 (en) * 2000-01-06 2002-07-02 Bryan M. Clay Methods and kits for maxillary dental anesthesia by means of a nasal deliverable anesthetic
US20030119892A1 (en) * 2001-01-05 2003-06-26 Larry Caldwell Methods and compositions for treating headache pain with topical NSAID compositions
US20040204366A1 (en) * 2001-04-27 2004-10-14 Gavril Pasternak Topical anesthetic/opioid formulation and uses thereof
US20050142072A1 (en) * 2002-03-19 2005-06-30 Birch Phillip J. Analgesics for nasal administration
US20030185872A1 (en) * 2002-03-27 2003-10-02 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198240B2 (en) 2005-08-26 2012-06-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
US8202838B2 (en) 2005-08-26 2012-06-19 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
US8252745B2 (en) 2005-08-26 2012-08-28 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
US8258096B2 (en) 2005-08-26 2012-09-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
US8501691B2 (en) 2005-08-26 2013-08-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
US9629894B2 (en) 2015-01-07 2017-04-25 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use
US11389473B2 (en) 2015-01-07 2022-07-19 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use

Also Published As

Publication number Publication date
JP2009506071A (en) 2009-02-12
WO2007025286A2 (en) 2007-03-01
US8202838B2 (en) 2012-06-19
JP5670415B2 (en) 2015-02-18
IL189777A0 (en) 2008-08-07
EP2179741A1 (en) 2010-04-28
US20120028898A1 (en) 2012-02-02
CA2620364A1 (en) 2007-03-01
EP2179741B1 (en) 2014-10-15
US8198240B2 (en) 2012-06-12
US20090317377A1 (en) 2009-12-24
US8252745B2 (en) 2012-08-28
WO2007025249A2 (en) 2007-03-01
JP2012207046A (en) 2012-10-25
US20090181880A1 (en) 2009-07-16
WO2007025249A3 (en) 2007-04-19
EP2056800A2 (en) 2009-05-13
AU2006282799A1 (en) 2007-03-01
CA2620202C (en) 2016-10-04
AU2006282799B2 (en) 2012-11-29
US20110250212A1 (en) 2011-10-13
JP5276982B2 (en) 2013-08-28
US8258096B2 (en) 2012-09-04
EP1928484A2 (en) 2008-06-11
JP2013060464A (en) 2013-04-04
JP2009506076A (en) 2009-02-12
EP1928484B1 (en) 2010-02-24
US20090291900A1 (en) 2009-11-26
US20120322736A1 (en) 2012-12-20
US20070054843A1 (en) 2007-03-08
DE602006012513D1 (en) 2010-04-08
US20100080797A1 (en) 2010-04-01
ATE458491T1 (en) 2010-03-15
US20070093420A1 (en) 2007-04-26
CA2620202A1 (en) 2007-03-01
US8501691B2 (en) 2013-08-06
EP2056800B1 (en) 2015-12-09

Similar Documents

Publication Publication Date Title
WO2007025286A3 (en) Therapy procedure for drug delivery for trigeminal pain
WO2008054544A3 (en) Method for delivery across the blood brain barrier
WO2008021113A3 (en) Transdermal methods and systems for treating alzheimer's disease
WO2008036682A3 (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
MX2011001384A (en) Compositions and methods for treating psychiatric disorders.
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2007024841A3 (en) Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
WO2003070191A8 (en) Tamper-resistant transdermal opioid delivery devices
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
WO2008070149A3 (en) Prodrugs and methods of making and using the same
WO2005107726A3 (en) Method for the treatment of back pain
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
WO2007100675A3 (en) Collagenase for treating cellulite
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2008029237A3 (en) Combination therapies for rheumatoid arthritis
WO2006036770A3 (en) Combination therapy for the treatment of obesity
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
WO2008045378A3 (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2007143185A3 (en) Transdermal treatment of tendinopathy using glyceryl trinitrite
WO2006081127A3 (en) Compositions and therapeutic methods utilizing a combination of a 5-ht1f inhibitor and an nsaid
WO2007100590A3 (en) Methods for treating cellulite
WO2006078870A3 (en) Methods for treating adhesive capsulitis

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2620202

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008528248

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006813886

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06813886

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11990878

Country of ref document: US